Evidence map›Paper›PMID 32152876›Full record

Observational studyInternational journal of hematology2020

Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line.

Masatoshi Sakurai, Shinichiro Okamoto, Itaru Matsumura, Satsuki Murakami, Makiko Takizawa, Masato Waki, Daiki Hirano, Reiko Watanabe-Nakaseko, Naoki Kobayashi, Masaki Iino and 11 more

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Real-world Management of CML: Outcomes and Treatment Patterns.Current hematologic malignancy reports · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 1 country.

Masatoshi SakuraiDivision of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. sakurai@z5.keio.jp.
Shinichiro OkamotoDivision of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Satsuki MurakamiDepartment of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
Makiko TakizawaDepartment of Hematology, Gunma University Hospital, Gunma, Japan.
Masato WakiDepartment of Hematology, Kagawa Prefectural Central Hospital, Kagawa, Japan.
Daiki HiranoDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Reiko Watanabe-NakasekoDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Naoki KobayashiDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Masaki IinoDepartment of Hematology and Hematopoietic Stem Cell Transplantation, Yamanashi Prefectural Central Hospital, Yamanashi, Japan.
Hideki MitsuiDepartment of Hematology, Otemae Hospital, Osaka, Japan.
Yuichi IshikawaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Naoto TakahashiDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
Tatsuya KawaguchiDepartment of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan.
Ritsuro SuzukiDepartment of Oncology and Hematology, Shimane University Hospital, Izumo, Japan.
Kazuhito YamamotoDepartment of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
Masahiro KizakiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Kazunori OhnishiTokai-Hokuriku Block Blood Center, Seto, Japan.
Tomoki NaoeDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan.
New TARGET investigators
Aichi Cancer Center · JPKeio University · JPNational Hospital Organization · JPKumamoto Health Science University · JPKyushu University · JPOtemae Hospital · JPSapporo Hokuyu Hospital · JPAkita University · JPKagawa Prefectural Central Hospital · JPSocial Insurance Saitama Chuo Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report the results of the New TARGET study 2nd-line, which collected data on patients with chronic-phase (CP) chronic myeloid leukemia (CML) who received a 2nd-line tyrosine kinase inhibitor (TKI) because of resistance and/or to a 1st-line TKI. A total of 98 patients were enrolled intolerance between April 2010 and March 2013, and 82 patients were analyzed. The median age was 54 years (range 22-88 years). Seventy-six patients (93%) received imatinib as the 1st-line TKI. Forty-five (55%) and 37 (45%) patients began nilotinib and dasatinib treatments at entry, respectively. First-line TKI treatment achieved complete hematological response in 79 patients (96%) and complete cytogenetic response (CCyR) in 49 patients (60%), respectively. Nine patients (11%) had BCR-ABL1 kinase domain point mutations at enrollment. The estimated 3-year progression-free-survival rate after enrollment was 98.7% (95% CI 91.1-99.8%). Overall, the probabilities of achieving CCyR and a major molecular response were 89.3% (95% CI 81.4-94.8%) and 87.2% (95% CI 78.1-93.8%), respectively. There were no new safety issues. This study demonstrated that CML-CP patients in Japan who are resistant and/or intolerant to a 1st-line TKI can achieve an extremely good outcome by 2nd-line TKI treatment.

Indexed as

AdultAgedAged, 80 and overDasatinibDrug Resistance, NeoplasmFemaleFusion Proteins, bcr-ablHumansImatinib MesylateJapanLeukemia, Myeloid, Chronic-PhaseMaleMiddle AgedPoint MutationProspective StudiesProtein Kinase InhibitorsDasatinibFusion Proteins, bcr-ablImatinib MesylateProtein Kinase InhibitorsProtein-Tyrosine KinasesChronic myeloid leukemiaJapanObservational studyResistance or intoleranceTyrosine kinase inhibitors

Identifiers

PMID32152876
OpenAlexW3012433646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.